Related Experiment Videos
Activated protein C resistance in type I diabetes
G Gruden1, C Olivetti, P Cavallo-Perin
1Department of Internal Medicine, University of Turin, Italy.
Diabetes Care
|March 1, 1997
Summary
Type I diabetes patients show reduced activated protein C (aPC) sensitivity compared to healthy individuals. This suggests potential abnormalities in the protein C/S inhibiting system in diabetic patients.
Area of Science:
- Endocrinology
- Hematology
- Thrombosis Research
Background:
- Type I diabetes is a complex metabolic disorder.
- Coagulation disorders are a known complication in diabetes.
- The protein C system plays a crucial role in regulating blood coagulation.
Purpose of the Study:
- To investigate activated protein C (aPC) sensitivity in type I diabetic patients.
- To compare aPC sensitivity between type I diabetic patients and healthy controls.
Main Methods:
- A cohort of 37 type I diabetic patients and 33 healthy controls were studied.
- Exclusion criteria included history of venous thrombosis, coagulation disorders, infections, and cardiovascular complications.
- Activated partial thromboplastin time (aPTT) with and without aPC was measured to determine the aPC ratio.
Main Results:
- The activated protein C ratio was significantly lower in type I diabetic patients compared to healthy controls (P = 0.005).
- This indicates reduced sensitivity to activated protein C in the diabetic group.
Conclusions:
- The findings suggest that the terminal steps of the protein C/S inhibiting system may be impaired in type I diabetes.
- Further research is warranted to elucidate the specific mechanisms and clinical implications of these findings.